Toxicogenomics and drug discovery: will new technologies help us produce better drugs?
Toxicogenomics and drug discovery: will new technologies help us produce better drugs?
复制标题
DOI：
10.1038/nrd710
复制
发表时间：
2002-01-01
影响因子：
120.1
通讯作者：
Friend, SH
中科院分区：
文献类型：
--
作者：
Ulrich, R;Friend, SH
20世纪80年代后期有报道称大多数候选药物在研发过程中失败，药物研发项目因此做出反应，想出办法增加研发过程中的化学物质数量。由于如今的研发主要由化学和高通量筛选驱动，新化合物的生物效应，尤其是毒性，在化合物进入研发阶段之前基本不被了解。可以说，这种模式导致了更多的失败，而不是随着有更多的化学物质可供研究就带来更多成功，在启动成本高昂的研发研究之前，对任何一种单一药剂的了解都更少。毒理基因组学这一新兴领域使我们能够在很早的时候就对药物效应提出详细的问题，从而从根本上改变我们的药物研发方法。
Acting on reports in the late 1980s that most drug candidates fall in development, pharmaceutical discovery programmes responded by devising ways to increase the number of chemicals in the pipeline. With discovery now driven primarily by chemistry and high-throughput screening, the biological effects and, in particular, the toxicity of new compounds are largely not appreciated until a compound enters development. Arguably, this paradigm has produced more failures rather than delivering more successes with more chemicals to examine, much less is known about any single agent before costly development studies are initiated. The emerging field of toxicogenomics is enabling us to ask detailed questions about drug effects very early on, thereby fundamentally changing our approach to drug discovery.